Ondine Biomedical's Steriwave Technology Promises Substantial UK Savings

A recent study by the York Health Economics Consortium (YHEC) highlights potential savings for UK hospitals using Ondine Biomedical's Steriwave technology. Implementing Steriwave nasal decolonization prior to surgeries may result in an annual reduction of £200 million, equating to savings of £2.38 for every £1 invested.

The analysis revealed significant economic advantages across multiple surgical areas. For example, cardiac surgeries showed the highest savings, with potential returns up to £3.92 per £1 spent. In hip and knee surgeries, net savings per 1,000 patients could reach £86,650 and £84,430, respectively.

These findings coincide with clinical data from Mid Yorkshire Teaching NHS Trust, reporting Steriwave prevents 0.98% more surgical site infections per 1,000 patients than current protocols.

CEO Carolyn Cross emphasized the importance of reducing health care costs while improving patient outcomes through infection prevention.